Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia

References

• Xia R, Mao ZH. Progression of motor symptoms in Parkinson’s disease. Neurosci Bull. 2012;28(1):39–48. doi:10.1007/s12264-012-1050-z22233888
   PubMed Web of Science ®Google Scholar
• Birtwistle J, Baldwin D. Role of dopamine in schizophrenia and Parkinson’s disease. Br J Nurs. 1998;7(14):832–834, 836, 838–841. doi:10.12968/bjon.1998.7.14.5636
   Google Scholar
• Yabe I, Ohta M, Egashira T, et al. Effectiveness of zonisamide in a patient with Parkinson’s disease and various levodopa-induced psychotic symptoms. Neurol Clin Neurosci. 2014;2(6):201–203. doi:10.1111/ncn3.126
   Google Scholar
• Bohlega SA, Al-Foghom NB. Drug-induced Parkinson`s disease. A clinical review. Neurosciences (Riyadh). 2013;18(3):215–221.23887211
   PubMed Web of Science ®Google Scholar
• Caligiuri MP, Teulings HL, Dean CE, Niculescu AB, Lohr JB. Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics. Psychiatry Res. 2010;177(1):77–83. doi:10.1016/j.psychres.2009.07.00520381875
   PubMed Web of Science ®Google Scholar
• Fernández CP, Aguilar S, Viçens V, et al. ECT in a patient with Parkinson’s disease and schizophrenia, with dopamine transporter visualization using 123I-ioflupane SPET. J Neural Transm. 2011;118(4):647–650. doi:10.1007/s00702-011-0615-821359970
   PubMed Web of Science ®Google Scholar
• Gupta AK, Swarnkar S, Khunger GK, et al. Dopamine based pharmaco-therapeutics of schizophrenia and Parkinson’s disease: two ends of one spectrum. Ann Pharmacol Pharm. 2017;2(21):1109.
   Google Scholar
• Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665–682. doi:10.2165/00002512-200825080-0000418665659
   PubMed Web of Science ®Google Scholar
• Rukmangadachar LA, Kataria J, Hariprasad G, et al. Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients. Clin Proteomics. 2011;8(1):4. doi:10.1186/1559-0275-8-221906353
   PubMedGoogle Scholar
• Hariprasad G, Hariprasad R, Kumar L, Srinivasan A, Kola S, Kaushik A. Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. Biomarkers. 2013;18(6):532–541. doi:10.3109/1354750X.2013.82256123902290
   PubMed Web of Science ®Google Scholar
• Sehrawat U, Pokhriyal R, Gupta AK, et al. Proteomic analysis of advanced ovarian cancer tissue to identify potential biomarkers of responders and nonresponders to first-line chemotherapy of carboplatin and paclitaxel. Biomark Cancer. 2016;16(8):43–56.
   Google Scholar
• Kataria J, Rukmangadachar LA, Hariprasad G, O J, Tripathi M, Srinivasan A. Two dimensional difference gel electrophoresis analysis of cerebrospinal fluid in tuberculous meningitis patients. J Proteomics. 2011;74(10):2194–2203. doi:10.1016/j.jprot.2011.06.02021723968
   PubMed Web of Science ®Google Scholar
• Manral P, Sharma P, Hariprasad G, Chandralekha, Tripathi M, Srinivasan A. Can apolipoproteins and complement factors be biomarkers of Alzheimer’s disease? Curr Alzheimer Res. 2012;9(8):935–943.22631439
   PubMed Web of Science ®Google Scholar
• Gupta AK, Rani K, Swarnkar S, et al. Evaluation of serum apolipoprotein e as a potential biomarker for pharmacological therapeutic efficacy monitoring in dopamine dictated disease spectrum of schizophrenia and Parkinson’s disease: a Preliminary Study. J Cent Nerv Syst Dis. 2018;10:1179573518803585.eCollection. doi:10.1177/1179573518803585
   Web of Science ®Google Scholar
• Gupta AK, Kumar GK, Rani K, et al. 2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine dictated states of Parkinson’s disease and schizophrenia. Neuropsych Dis Treat. 2019;15:1031–1044. doi:10.2147/NDT.S198559
   Web of Science ®Google Scholar
• Gupta AK, Pokhriyal R, Das U, et al., Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in CSF to monitor pharmaco-therapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia. Neuropsych Dis Treat. 2019;15:2073–2085. doi:10.2147/NDT.S205550
   Web of Science ®Google Scholar
• Chou KL, Taylor JL, Patil PG. The MDS–UPDRS tracks motor and non–motor improvement due to sub-thalamic nucleus deep brain stimulation in Parkinson disease. Parkinsonism Relat Disord. 2013;19(11):966–969. doi:10.1016/j.parkreldis.2013.06.01023849499
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendation. Mov Disord. 2004;19:1020–1028. doi:10.1002/mds.2021315372591
   PubMed Web of Science ®Google Scholar
• World Health Organization Geneva. The ICD-10 Classification of Mental and Behavioural Disorders; 1993.
   Google Scholar
• Ganapathiraju MK, Thahir M, Handen A, et al. Schizophrenia interactome with 504 novel protein-protein interactions. NPJ Schizophr. 2016;2:16012. doi:10.1038/npjschz.2016.1227336055
   PubMed Web of Science ®Google Scholar
• Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–432. doi:10.1093/bioinformatics/btq67521149340
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• Gao J, Ade AS, Tarcea VG, et al. Integrating and annotating the interactome using the MiMI plugin for cytoscape. Bioinformatics. 2009;25(1):137–138. doi:10.1093/bioinformatics/btn50118812364
   PubMed Web of Science ®Google Scholar
• Jensen LJ, Kuhn M, Stark M, et al. STRING 8–a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412–D416. doi:10.1093/nar/gkn76018940858
   PubMed Web of Science ®Google Scholar
• Chatr-aryamontri A, Ceol A, Palazzi LM, et al. MINT: the molecular INTeraction database. Nucleic Acids Res. 2007;35(Databaseissue):D572–D574. doi:10.1093/nar/gkl95017135203
   PubMed Web of Science ®Google Scholar
• Keshava Prasad TS, Goel R, Kandasamy K, et al. Human protein reference database–2009 update. Nucleic Acids Res. 2009;37(Databaseissue):D767–D772. doi:10.1093/nar/gkn89218988627
   PubMed Web of Science ®Google Scholar
• Loke H, Harley V, Lee J. Biological factors underlying sex differences in neurological disorders. Int J Biochem Cell Biol. 2015;65:139–150. doi:10.1016/j.biocel.2015.05.02426028290
   PubMed Web of Science ®Google Scholar
• Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022. doi:10.1093/aje/kwg06812777365
   PubMed Web of Science ®Google Scholar
• Sham PC, MacLean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand. 1994;89(2):135–141. doi:10.1111/j.1600-0447.1994.tb01501.x8178665
   PubMed Web of Science ®Google Scholar
• Guezguez B, Vigneron P, Lamerant N, Kieda C, Jaffredo T, Dunon D. Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor. J Immunol. 2007;179(10):6673–6685. doi:10.4049/jimmunol.179.10.667317982057
   PubMed Web of Science ®Google Scholar
• Flanagan K, Fitzgerald K, Baker J, et al. Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS One. 2012;7(7):e40443. doi:10.1371/journal.pone.004044322792325
   PubMed Web of Science ®Google Scholar
• Schneider-Hohendorf T, Rossaint J, Mohan H, et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med. 2014;211(9):1833–1846. doi:10.1084/jem.2014054025135296
   PubMed Web of Science ®Google Scholar
• Liu Z, Huang Y, Cao BB, Qiu Y-H, Peng Y-P. Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 Interaction in a mouse model of Parkinson’s disease. Mol Neurobiol. 2017;54(10):7762–7776. doi:10.1007/s12035-016-0249-927844285
   PubMed Web of Science ®Google Scholar
• Reynolds AD, Stone DK, Hutter JA, et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261–2271. doi:10.4049/jimmunol.090185220118279
   PubMed Web of Science ®Google Scholar
• Borovcanin M, Jovanovic I, Radosavljevic G, et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res. 2012;46(11):1421–1426. doi:10.1016/j.jpsychires.2012.08.01622974591
   PubMed Web of Science ®Google Scholar
• Angeles DC, Gan BH, Onstead L, et al. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat. 2011;32(12):1390–1397. doi:10.1002/humu.2158221850687
   PubMed Web of Science ®Google Scholar
• Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain. 2005;128(Pt11):2665–2674. doi:10.1093/brain/awh62516219675
   PubMed Web of Science ®Google Scholar
• Cao S, Theodore S, Standaert DG. Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson’s disease. Mol Neurodegener. 2010;26:5–42.
   Google Scholar
• Ulvestad E, Williams K, Vedeler C, et al. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci. 1994;121(2):125–131. doi:10.1016/0022-510x(94)90340-98158203
   PubMed Web of Science ®Google Scholar
• Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002;99(22):14524–14529. doi:10.1073/pnas.17251459912376616
   PubMed Web of Science ®Google Scholar
• Lira A, Kulczycki J, Slack R, Anisman H, Park DS. Involvement of the Fc gamma receptor in a chronic N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of dopaminergic loss. J Biol Chem. 2011;286(33):28783–28793. doi:10.1074/jbc.M111.24483021693708
   PubMed Web of Science ®Google Scholar
• Cao S, Standaert DG, Harms AS. The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J Neuroinflammation. 2012;9:259. doi:10.1186/1742-2094-9-25923186369
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479–492. doi:10.1016/j.semnephrol.2013.08.00124161035
   PubMed Web of Science ®Google Scholar
• Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–797. doi:10.1038/ni.192320720586
   PubMed Web of Science ®Google Scholar
• Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers. 2005;21(2):93–101. doi:10.1155/2005/80657315920296
   PubMed Web of Science ®Google Scholar
• Goldknopf IL, Sheta EA, Bryson J, et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson’s disease. Biochem Biophys Res Commun. 2006;342(4):1034–1039. doi:10.1016/j.bbrc.2006.02.05116516157
   PubMed Web of Science ®Google Scholar
• Bodea L-G, Wang Y, Linnartz-Gerlach B, et al. Neurodegeneration by activation of the microglial complement-phagosome pathway. J Neurosci. 2014;34(25):8546–8556. doi:10.1523/JNEUROSCI.5002-13.201424948809
   PubMed Web of Science ®Google Scholar
• Loeffler DA, Camp DM, Conant SB. Complement activation in the Parkinson’s disease substantia nigra: an immunocytochemical study. J Neuroinflammation. 2006;3:29. doi:10.1186/1742-2094-3-2917052351
   PubMed Web of Science ®Google Scholar
• Erikson J, Martinis J, Croce CM. Assignment of the genes for human lambda immunoglobulin chains to chromosome 22. Nature. 1981;294(5837):173–175. doi:10.1038/294173a06795508
   PubMed Web of Science ®Google Scholar
• Rolland T, Taşan M, Charloteaux B, et al. A proteome-scale map of the human interactome network. Cell. 2014;159(5):1212–1226. doi:10.1016/j.cell.2014.10.05025416956
   PubMed Web of Science ®Google Scholar
• Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature. 2005;437(7062):1173–1178. doi:10.1038/nature0420916189514
   PubMed Web of Science ®Google Scholar
• Mah AL, Perry G, Smith MA, Monteiro MJ. Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation. J Cell Biol. 2000;151(4):847–862. doi:10.1083/jcb.151.4.84711076969
   PubMed Web of Science ®Google Scholar
• Stieren ES, El Ayadi A, Xiao Y, et al. Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J Biol Chem. 2011;286(41):35689–35698. doi:10.1074/jbc.M111.24314721852239
   PubMed Web of Science ®Google Scholar
• Schulte EC, Fukumori A, Mollenhauer B, et al. Rare variants in β-Amyloid precursor protein (APP) and Parkinson’s disease. Eur J Hum Genet. 2015;23(10):1328–1333. doi:10.1038/ejhg.2014.30025604855
   PubMed Web of Science ®Google Scholar
• Altar CA, Jurata LW, Charles V, et al. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry. 2005;58(2):85–96. doi:10.1016/j.biopsych.2005.03.03116038679
   PubMed Web of Science ®Google Scholar
• Bousman CA, Chana G, Glatt SJ, et al. Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):494–502. doi:10.1002/ajmg.b.3100619582768
   PubMed Web of Science ®Google Scholar
• Rubio MD, Wood K, Haroutunian V, Meador-Woodruff JH. Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia. Neuropsychopharmacology. 2013;38(10):1910–1920. doi:10.1038/npp.2013.8423571678
   PubMed Web of Science ®Google Scholar
• Rehman AA, Ahsan H, Khan FH. α-2-Macroglobulin: a physiological guardian. J Cell Physiol. 2013;228(8):1665–1675. doi:10.1002/jcp.2426623086799
   PubMed Web of Science ®Google Scholar
• Hu YQ, Koo PH. Inhibition of phosphorylation of TrkB and TrkC and their signal transduction by alpha2-macroglobulin. J Neurochem. 1998;71(1):213–220. doi:10.1046/j.1471-4159.1998.71010213.x9648868
   PubMed Web of Science ®Google Scholar
• Hu YQ, Dluzen DE, Koo PH. Intracranial infusion of monoamine‐activated α2‐Macroglobulin decreases dopamine concentrations within the rat caudate putamen. J Neurosci Res. 1994;38(5):531–537. doi:10.1002/jnr.4903805067529325
   PubMed Web of Science ®Google Scholar
• Koo PH, Liebl DJ, Qiu WS, Hu YQ, Dluzen DE. Monoamine-activated α2-macroglobulin inhibits neurite outgrowth, survival, choline acetyltransferase, and dopamine concentration of neurons by blocking neurotrophin-receptor (trk) phosphorylation and signal transduction. Ann N Y Acad Sci. 1994;737:460–464. doi:10.1111/j.1749-6632.1994.tb44340.x7524422
   PubMed Web of Science ®Google Scholar
• Hu YQ, Liebl DJ, Dluzen DE, Koo PH. Inhibition of dopamine and choline acetyltransferase concentrations in rat CNS neurons by rat alpha 1- and alpha 2-macroglobulins. J Neurosci Res. 1998;51(4):541–550. doi:10.1002/(SICI)1097-4547(19980215)51:4<541::AID-JNR14>3.0.CO;2-69514208
   PubMed Web of Science ®Google Scholar
• Morgan DG, May PC, Finch CE. Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am Geriatr Soc. 1987;35(4):334–345. doi:10.1111/j.1532-5415.1987.tb04641.x3549845
   PubMed Web of Science ®Google Scholar
• Cheng MH, Bahar I. Molecular mechanism of dopamine transport by human dopamine transporter. Structure. 2015;23(11):2171–2181. doi:10.1016/j.str.2015.09.00126481814
   PubMed Web of Science ®Google Scholar
• Sidhu A, Wersinger C, Vernier P. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson’s disease. FEBS Lett. 2004;565(1–3):1–5. doi:10.1016/j.febslet.2004.03.06315135042
   PubMed Web of Science ®Google Scholar
• Chen MK, Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease. J Neurochem. 2008;105(1):78–90. doi:10.1111/j.1471-4159.2007.05108.x17988241
   PubMed Web of Science ®Google Scholar
• Pifl C, Rajput A, Reither H, et al. Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci. 2014;34(24):8210–8218. doi:10.1523/JNEUROSCI.5456-13.201424920625
   PubMed Web of Science ®Google Scholar
• Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res. 2003;5(3):165–176.12835121
   PubMed Web of Science ®Google Scholar
• Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparansulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40(1):1–6.9869645
   PubMed Web of Science ®Google Scholar
• Iwai A. Properties of NACP/alpha-synuclein and its role in Alzheimer’s disease. Biochim Biophys Acta. 2000;1502(1):95–109. doi:10.1016/s0925-4439(00)00036-310899435
   PubMed Web of Science ®Google Scholar
• Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97–115. doi:10.1177/026988111456363425586400
   PubMed Web of Science ®Google Scholar
• Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570–580. doi:10.1002/ana.2231121400565
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson disease and other synucleinopathies. Brain. 2012;35:1900–1913. doi:10.1093/brain/aws055
   Web of Science ®Google Scholar
• Miller C, Kirchmair R, Troger J, et al. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P,and peptides derived from om chromogranin A (GE-25) and secretogranin II(secretoneurin). Biol Psychiatry. 1996;39(11):911–918. doi:10.1016/0006-3223(95)00098-49162202
   PubMed Web of Science ®Google Scholar
• Soler-López M, Zanzoni A, Lluís R, Stelzl U, Aloy P. Interactome mapping suggests new mechanistic details underlying Alzheimer’s disease. Genome Res. 2011;21(3):364–376. doi:10.1101/gr.114280.11021163940
   PubMed Web of Science ®Google Scholar
• Chen RH, Wislet-Gendebien S, Samuel F, et al. α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J Biol Chem. 2013;288(11):7438–7449. doi:10.1074/jbc.M112.43949723344955
   PubMed Web of Science ®Google Scholar
• Gitler AD, Bevis BJ, Shorter J, et al. The Parkinson’s disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A. 2008;105(1):145–150. doi:10.1073/pnas.071068510518162536
   PubMed Web of Science ®Google Scholar
• Wang Y, Hancock AM, Bradner J, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. Am J Pathol. 2011;178(4):1509–1516. doi:10.1016/j.ajpath.2011.01.00621435440
   PubMed Web of Science ®Google Scholar
• Xiong Y, Yuan C, Chen R, Dawson TM, Dawson VL. ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci. 2012;32(11):3877–3886. doi:10.1523/JNEUROSCI.4566-11.201222423108
   PubMed Web of Science ®Google Scholar
• Hiltunen M, Lu A, Thomas AV, et al. Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion. J Biol Chem. 2006;281(43):32240–32253. doi:10.1074/jbc.M60310620016945923
   PubMed Web of Science ®Google Scholar
• Huang X, Dai FF, Gaisano G, et al. The identification of novel proteins that interact with the GLP-1 receptor and restrain its activity. Mol Endocrinol. 2013;27(9):1550–1563. doi:10.1210/me.2013-104723864651
   PubMedGoogle Scholar
• Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009;106(4):1285–1290. doi:10.1073/pnas.080672010619164583
   PubMed Web of Science ®Google Scholar
• Marazziti D, Mandillo S, Di Pietro C, et al. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc Natl Acad Sci U S A. 2007;104(23):9846–9851. doi:10.1073/pnas.070336810417519329
   PubMed Web of Science ®Google Scholar
• Huttlin EL, Ting L, Bruckner RJ, et al. The BioPlex network: a systematic exploration of the human interactome. Cell. 2015;162(2):425–440. doi:10.1016/j.cell.2015.06.04326186194
   PubMed Web of Science ®Google Scholar
• Huttlin EL, Bruckner RJ, Paulo JA, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545(7655):505–509. doi:10.1038/nature2236628514442
   PubMed Web of Science ®Google Scholar
• John S, Mishra R. mRNA Transcriptomics of galectins unveils heterogeneous organization in mouse and human brain. Front Mol Neurosci. 2016;9:139. doi:10.3389/fnmol.2016.0013928018170
   PubMed Web of Science ®Google Scholar
• Brieger A, Adryan B, Wolpert F, Passmann S, Zeuzem S, Trojan J. Cytoskeletal scaffolding proteins interact with Lynch-Syndrome associated mismatch repair protein MLH1. Proteomics. 2010;10(18):3343–3355. doi:10.1002/pmic.20090067220706999
   PubMed Web of Science ®Google Scholar
• Chen TC, Lin KT, Chen CH, et al. Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network. J Proteome Res. 2014;13(12):5339–5346. doi:10.1021/pr500273725241761
   PubMed Web of Science ®Google Scholar
• Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc Natl Acad Sci U S A. 2000;97(6):2875–2880. doi:10.1073/pnas.04055659710688892
   PubMed Web of Science ®Google Scholar
• Thomas EA, George RC, Sutcliffe JG. Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. Prostaglandins Leukot Essent Fatty Acids. 2003;69(6):421–427.14623496
   PubMed Web of Science ®Google Scholar
• Horrobin DF, Ally AI, Karmali RA, Karmazyn M, Manku MS, Morgan RO. Prostaglandins and schizophrenia: further discussion of the evidence. Psychol Med. 1978;8(1):43–48. doi:10.1017/s0033291700006619635069
   PubMed Web of Science ®Google Scholar
• Martins-de-Souza D, Maccarrone G, Wobrock T, et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res. 2010;44(16):1176–1189. doi:10.1016/j.jpsychires.2010.04.01420471030
   PubMed Web of Science ®Google Scholar
• Magdalinou NK, Noyce AJ, Pinto R, et al. Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism Relat Disord. 2017;37:65–71. doi:10.1016/j.parkreldis.2017.01.01628214264
   PubMed Web of Science ®Google Scholar
• Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293–348.16914840
   PubMed Web of Science ®Google Scholar